Clinical Trial Finder

Inclusion Criteria:

• - >= 18 years of age.

• - Preoperative imaging characteristics consistent with brain glioblastoma (magnetic resonance imaging [MRI] brain) - Patients who are undergoing neurosurgical resection for treatment of glioblastoma.

• - Ability to understand and willingness to sign an informed consent form.

• - Ability to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

• - Prior treatment for glioblastoma.

• - Glioblastoma size less than 5 cm^3.

• - Known allergy against amide type of local anesthetics.

• - History of severe cardiac failure (determined by clinical history of less the 3 Metabolic Equivalent of Tasks [METs]) - 2nd or 3rd degree heart block (exception: patients with pacemaker) - Concurrent treatment with class I or III antiarrhythmics (phenytoin, procainamide, propranolol, quinidine) or amiodarone use =< 3 months.

• - History of Wolff-Parkinson-White syndrome, Stokes Adams syndrome, or active dysrhythmia.

• - History of bradycardia.

• - Prior clinical history of severe hepatic impairment or alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 1.55 times of upper normal limit.

• - Prior clinical history of severe renal impairment or estimated glomerular filtration rate (EGFR) < 30ml/min.

• - Uncontrolled seizure disorder.

• - Acute porphyria.

• - Patients requiring an awake fiberoptic intubation due to administration of additional lidocaine.

• - Pregnant or lactating women.

• - Any condition that would prohibit the understanding or rendering of informed consent.

• - Any medical condition including additional malignancies, laboratory abnormalities, or psychiatric illness that in the opinion of the investigator would prevent the subject from participating and adhering to study related procedures.

- Uncontrolled concomitant disease that in the opinion of the investigator would interfere with the patient's safety or compliance on trial

PRIMARY OBJECTIVE:

• I. To assess the pharmacokinetic properties of intravenously administered lidocaine inside a glioblastoma tumor by means of mass spectroscopy.

SECONDARY OBJECTIVE:

• I. To assess the differences in overall survival (OS) and progression free survival (PFS) between the patients in the lidocaine therapy group and historical controls taken from the literature (Stupp et al) with comparable post-operative treatment regimen.

OUTLINE: Patients receive bolus lidocaine intravenously (IV) per standard of care. After intubation, patients receive another infusion of lidocaine IV over 4 hours or until the end of surgery. Patients also undergo collection of blood and tumor samples at the start of surgery and hourly afterwards until a total of 4 samples are collected. After completion of surgery, patients are followed for 24 hours, and at 7-14 days, up to 30 days.

Arms

Experimental: Health services research (lidocaine, surgery)

Patients receive bolus lidocaine IV per standard of care. After intubation, patients receive another infusion of lidocaine IV over 4 hours or until the end of surgery. Patients also undergo collection of blood and tumor samples at the start of surgery and hourly afterwards until a total of 4 samples are collected.

Interventions

Procedure: - Biospecimen Collection

Undergo collection of blood and tumor samples

Drug: - Lidocaine

Given IV

Procedure: - Resection

Undergo surgical resection per standard of care